New Delhi, May 12 -- Biocon Group's board is setting up a committee to evaluate strategic restructuring options, including a merger of its biosimilars arm Biocon Biologics Ltd with its flagship Biocon Ltd.

The options would be evaluated taking into consideration matters relating to legal and tax aspects and subject to all approvals, including regulatory, board and shareholders, the company said in a release dated 8 May.

The company had said in February that it would likely list its biosimilars business on the stock exchanges by March 2026.

Also read: Biocon share price jumps 4% as subsidiary secures market entry for Yesafili in US

".given the market volatility that we are seeing on the IPO front, the board was of the opinion that we s...